AI-generated personalized treatments that increase efficacy and reduce systemic toxicity via the ATT-AI Platform Precision targeting and delivery of the best predicted agents directly to the tumor microenvironment via ATTImmune Technology
ATT-AI is Attivare's AI powered platform for personalizing immune agonist selection. By analyzing single-cell RNA sequencing data from patient tumors, ATT-AI identifies which immune agonists, loaded onto ATTImmune, are most likely to reprogram that patient's specific tumor microenvironment.
Founded at the Wyss Institute at Harvard University, Attivare's proprietary biomaterial scaffold recruits and reprograms target immune cells directly within the tumor microenvironment providing 3D spatiotemporal controlled release of bioactive components.
Traditional immunotherapy floods the systemic circulation with immune-activating agents, where in many cases causing severe off-target toxicity. Attivare's approach is fundamentally different. Attivare uses its AI powered platform (ATT-AI) to select the optimum agonist or combination of agonists followed by placement on our biomaterial scaffold (ATTimmune) to deliver immune agonists directly into the tumor microenvironment, keeping therapeutic concentrations where they matter and out of the bloodstream.
The combination of AI data based predictions and localized delivery changes both the treatment paradigm, and the toxicity profile of immune agonists, enabling immune agonists to be safely administered to finally realize their potent anti-tumor potential.
ATT-AI is Attivare's AI-powered platform for personalizing immune agonist selection. By analyzing single-cell RNA sequencing data from patient tumors, ATT-AI identifies which immune agonists, loaded onto the ATTImmune, are most likely to reprogram that patient's specific tumor microenvironment.
Pre-treatment tumor profiling at single-cell resolution
Cell state predictions and agent ranking
Rank-ordered immune agonist candidates per patient
Traditional immune agonist approaches face fundamental pharmacological constraints. Attivare's multi-layered platform overcomes these barriers with biomaterial delivery, AI-driven design, and personalized immunotherapy.
Our ATTImmune Scaffold is engineered to create a new physical microenvironment within the tumor concentrating immune activity where it's needed and providing programmable release of therapeutic payloads.
Proprietary biomaterial scaffold provides structural support for a new immune-activating microenvironment. Intratumorally injectable via a standard gauge needle. Biodegradable and tunable for controlled payload release kinetics.
By concentrating immune agonists at the tumor site, ATTImmune achieves therapeutic concentrations locally while minimizing systemic exposure — dramatically improving the therapeutic window for potent immune agonists.
The scaffold recruits, activates, and releases tumor-specific immune cells. Loaded immunomodulators reprogram the suppressive tumor microenvironment generating durable systemic abscopal effects.
The ATTImmune scaffold is compatible with a broad library of immune agonists: cytokines, TLR agonists, checkpoint modulators, and combination regimen, which can easily be absorbed to the scaffold prior to administration. Combined with the ATT-AI intelligent agonist selection, the optimal agonist combination for each patient's tumor can be created.
The scaffold recruits, activates, and releases tumor-specific immune cells. Loaded immunomodulators reprogram the suppressive tumor microenvironment generating durable systemic abscopal effects.
| Program | Indication | Payload | Discovery | Preclinical | Phase I / II |
|---|---|---|---|---|---|
+ ATT-02 |
Solid tumors | IL-12 | |||
+ ATT-02+ |
Solid tumors | IL-12 & ATT-AI Chosen Agent | |||
+ ATT-01 |
Leukemia | CpG & GM-CSF | |||
|
+ ATT-03
Gates Foundation Funded
|
Infectious disease | Malaria Antigen & Adjuvant | |||
|
+ ATT-04
Gates Foundation Funded
|
Infectious disease | RNA Stealth |
AI-driven personalized cytokine selection delivered via ATTImmune biomaterial scaffold
Utilizing IL-12 and our innovative biomaterial, ATT-02+ ensures robust and reproducible delivery of ATT-AI agonist personalized to each patient, based on our ATT-AI technology, directly to the tumor microenvironment. This precision targeting administers the optimal dose right where it's needed, minimizing off-target effects and enhancing tolerability. Moreover, ATT-02+ biomaterial provides supplementary inflammatory signals that boost the immune response within the tumor microenvironment. Here, we are focusing on converting cold tumors into hot tumors. Converting a cold tumor to a hot tumor transforms a cancer that the immune system ignores into one that is infiltrated by immune cells, making it responsive to immunotherapy. Converting a cold to a hot tumor boosts immunogenicity, attracts T cells into the tumor, disrupts immunosuppressive signals, and using combination therapies like checkpoint inhibitors aims cancer visible to the immune system so immunotherapy can work effectively.
Intratumoral IL-12 delivery via mesoporous silica rod scaffold
ATT-02 [ATTImmune, IL-12] tackles a significant hurdle in tumor immunotherapy, especially for PD-1 resistant tumors. Utilizing innovative biomaterial, ATT-02 ensures robust and reproducible delivery of cytokine (IL-12) directly to the tumor microenvironment. This precision targeting administers the optimal dose right where it's needed, minimizing off-target effects and enhancing tolerability. Moreover, ATT-02's biomaterial provides supplementary inflammatory signals that boost the immune response within the tumor microenvironment.
Our achievements include compelling preclinical efficacy, modulation of the tumor microenvironment, notable abscopal (systemic) effects and complete response.
Subcutaneous biomaterial delivery for acute myeloid leukemia remission maintenance
ATT-01 [ATTImmune, GM-CSF, CpG] represents a groundbreaking approach to treating acute myeloid leukemia (AML). The primary goal of ATT-01 therapy is to maintain remission with a tolerable treatment, ultimately improving overall survival and quality of life for patients. Administered as a subcutaneous injection following standard chemotherapy, ATT-01 stands out due to its first-in-class status as a biomaterial therapeutic.
Tunable antigen and adjuvant co-delivery to enhance potency and durability of existing vaccines
ATT-03 is an innovative malaria vaccine candidate. Our goal is to enhance both the potency and durability of existing infectious disease vaccines, our first case being malaria, aiming to reduce the number of required injections and provide long-term protection. Leveraging ATTImmune technology, we facilitate the slow, tunable release of both antigen and adjuvant. This method is designed to optimize the immunogenic response, ensuring a more effective and sustained defense against malaria. This technology can be used for any vaccine to enhance activity obviating boosters. Currently funded through a Gates Foundation Grant.
Controlled RNA delivery to enable and improve treatment efficacy
ATT-04 is a development project to evaluate the controlled delivery of RNA to enable or improve the efficacy of treatment. Current funding is being provided by the Gates Foundation.
The tumor microenvironment is not just a barrier to immunotherapy — it is the target. By delivering immune activation precisely where the immunosuppression is thickest, we transform the pharmacology of cancer treatment.
The ATTImmune platform is grounded in a substantial body of peer-reviewed research developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University.
